Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection.
PMID: 15308845
2004
Journal of Korean medical science
Abstract: Serum samples were tested by the oligonucleotide chips designed for detection of wild-type YMDD motif, M552V and M552I.
Introduction: The most common mutants have a change at codon 552 from M to V (M552V) or from M to I (M552I).
Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.
PMID: 15311721
2004
International journal of clinical practice
Abstract: Genotypic analysis showed M552V, M552I and L528M mutations.
Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
PMID: 12526951
2003
The American journal of gastroenterology
Abstract: METHODS: Sequential serum samples from 10 consecutive patients with lamivudine resistance after liver transplantation were analyzed for viral genotype, precore mutants, and viral polymerase gene mutants (L528M, M552V, M552I) using restriction fragment length polymorphism.
[Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients].
Abstract: To detect YMDD mutants, YVDD (M552V), and YIDD (M552I), we used direct sequencing and the restriction fragment length polymorphism (RFLP) method.
Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
PMID: 14675262
2003
Journal of gastroenterology and hepatology
Abstract: M552I was detected before therapy in one patient but M552V became the domain strain after therapy.
Abstract: The replication ability of the M552V mutant strain might be stronger than that of the M552I mutant strain.
Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
Abstract: Major HBV mutants during breakthrough hepatitis were those with M552I in the YMDD motif of viral DNA polymerase/reverse transcriptase in 7 patients (54%), M552I/L528M in 4 patients (31%) and M552V/L528M in 2 patients (15%).
Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation.
Abstract: Hepatitis B virus sequence analysis revealed several mutations in the polymerase gene (L528M, M552I, M552V) as well as in the surface gene region encoding the immunogenic major hydrophilic loop of the small surface protein (G130N, M133T, D144G).
[Detection and identification of emergence of HBV YMDD motif mutation during lamivudine treatment by hybridization to an oligonucleotide array].
PMID: 15340547
2003
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: By direct sequencing of the PCR products, 11 cases were found to have YVDD with adenine741 changed into cytidine resulted in methionine552 changed into valine in which 6 cases with adenine669 changed into cytidine and leucine changed into methionine, 10 cases had YIDD motif mutation with guanosine743 altered thymidine methionine552 changed into isoleucine, including 3 cases with thymidine281 changed into cytidine and leucine565 altered proline.
Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.
PMID: 12121939
2002
Antimicrobial agents and chemotherapy
Abstract: The MCC-478 EC(50)s were 0.027 microM for wild-type HBV (about 20 times more efficient than lamivudine), 2.6 microM for M552I, 3.3 microM for M552V, and 2.0 microM for L528M/M552V.
Abstract: The emergence of resistant hepatitis B virus (HBV) with the L528M mutation and/or the M552V and M552I mutations in the polymerase gene following long-term lamivudine treatment is becoming an important clinical problem.
Abstract: The susceptibility of wild-type HBV and lamivudine-resistant mutants (M552I, M552V, and L528M/M552V) to MCC-478 was examined by transient tr
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
PMID: 11181644
2001
The Journal of clinical investigation
Abstract: After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant.
Abstract: The replication competency of the single C-domain mutants M552I and M552V was markedly decreased compared with that of wild-type HBV.
Abstract: We investigated the replication fitness and susceptibility of the wild-type and five mutant HBVs (L528M, M552I, M552V, L528M/M552I, and L52
HBV mutation literature information.
PMID: 
2004
Journal of Korean medical science
Browser Board
Co-occurred Entities
Filtrator
ViMRT